I78.0: Hereditary hemorrhagic telangiectasia
I78.0, hereditary hemorrhagic telangiectasia, is listed as a covered diagnosis in 3 Medicare billing and coding articles that apply to 12 HCPCS Level II codes, including Q5129 (Injection, bevacizumab-adcd (vegzelma), biosimilar, 10 mg), Q5126 (Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg), Q5118 (Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg). The articles come from 2 Medicare contractors. A listed diagnosis supports medical necessity only; coverage still depends on the LCD's criteria and on documentation in the medical record.
HCPCS Level II codes with I78.0 as a covered diagnosis
| Code | Description | Medicare coverage | DMEPOS fee 2026 (state range) | Articles listing it |
|---|---|---|---|---|
| Q5129 | Injection, bevacizumab-adcd (vegzelma), biosimilar, 10 mg | Carrier judgment | — | 1 |
| Q5126 | Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg | Carrier judgment | — | 1 |
| Q5118 | Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg | Carrier judgment | — | 1 |
| Q5107 | Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg | Special coverage instructions apply | — | 1 |
| J9035 | Injection, bevacizumab, 10 mg | Carrier judgment | — | 1 |
| J3590 | Unclassified biologics | Carrier judgment | — | 1 |
| C9257 | Injection, bevacizumab, 0.25 mg | Special coverage instructions apply | — | 1 |
| Q5160 | Injection, bevacizumab-nwgd (jobevne), biosimilar, 10 mg | Carrier judgment | — | 1 |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Special coverage instructions apply | — | 1 |
| G9998 | Documentation of medical reason(s) for an interval of less than 3 years since the last colonoscopy (e.g., last colonoscopy incomplete, last colonoscopy had inadequate prep, piecemeal removal of adenomas, or sessile serrated polyps >= 20 mm in size, last colonoscopy found greater than 10 adenomas, lower gastrointestinal bleeding, or patient at high risk for colon cancer due to underlying medical history ([i.e. crohn's disease, ulcerative colitis, personal or family history of colon cancer, hereditary colorectal cancer syndromes]) | Carrier judgment | — | 1 |
| G9999 | Documentation of system reason(s) for an interval of less than 3 years since the last colonoscopy (e.g., unable to locate previous colonoscopy report, patient cannot provide precise date or details from previous colonoscopy, previous colonoscopy report was incomplete) | Carrier judgment | — | 1 |
| J0585 | Injection, onabotulinumtoxina, 1 unit | Special coverage instructions apply | — | 1 |
Medicare policy articles listing I78.0
- A52370: Billing and Coding: Bevacizumab and biosimilars (Wellpoint Federal (MAC - Part A, MAC - Part B); 8 Level II codes)
- A56632: Billing and Coding: Colonoscopy/Sigmoidoscopy/Proctosigmoidoscopy (Palmetto GBA (MAC - Part A, MAC - Part B); 3 Level II codes). LCD with the same title: L34005, L34454
- A56389: Billing and Coding: Upper Gastrointestinal Endoscopy and Visualization (Palmetto GBA (MAC - Part A, MAC - Part B); 1 Level II codes). LCD with the same title: L34434
A diagnosis listed as covered in a billing and coding article supports medical necessity for the article's codes; it does not guarantee payment. Coverage depends on the LCD's criteria, the contractor's jurisdiction and documentation in the medical record.
Other I78 diagnoses (Diseases of capillaries)
- I78.8 — Other diseases of capillaries
Frequently asked questions
Does Medicare cover I78.0 (Hereditary hemorrhagic telangiectasia)?
Medicare covers items and services, not diagnoses. 3 Medicare billing and coding articles list I78.0 as a covered diagnosis for 12 HCPCS Level II codes: the diagnosis can support medical necessity for those codes, but payment still depends on the LCD's coverage criteria and the medical record.
Which HCPCS codes can be billed with ICD-10 I78.0?
The Level II codes from the policies most specific to this diagnosis are Q5129 (Injection, bevacizumab-adcd (vegzelma), biosimilar, 10 mg, 1 article); Q5126 (Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg, 1 article); Q5118 (Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg, 1 article); Q5107 (Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg, 1 article); J9035 (Injection, bevacizumab, 10 mg, 1 article). Code choice depends on the item supplied; check each code's descriptor.
Which Medicare policy articles list I78.0?
A52370 (Billing and Coding: Bevacizumab and biosimilars); A56632 (Billing and Coding: Colonoscopy/Sigmoidoscopy/Proctosigmoidoscopy); A56389 (Billing and Coding: Upper Gastrointestinal Endoscopy and Visualization).
What is ICD-10-CM code I78.0?
I78.0 is the ICD-10-CM code for hereditary hemorrhagic telangiectasia, in category I78 (Diseases of capillaries), chapter 9: Diseases of the circulatory system.
Next steps
- Run a reimbursement report for a device billed under Q5129
- Watch Q5129 for fee, coverage and descriptor changes
- Build a full Medicare revenue model for Q5129
Sources: CMS Medicare Coverage Database billing and coding articles (covered ICD-10 code lists and HCPCS links); ICD-10-CM FY2026; CMS HCPCS Level II release October 2026; CMS DMEPOS fee schedule 2026 (non-rural state fees). Not billing or legal advice.
Chapter 9: Diseases of the circulatory system · All diagnoses · HCPCS lookup